MYO7A_HUMAN,I589V,0.104,-,-,-
MYO7A_HUMAN,A595V,0.282,-,-,-
MYO7A_HUMAN,M599C,0.477,-,-,-
MYO7A_HUMAN,K605Q,0.517,Gain of ADP-ribosylation at R604 (Pr = 0.20 | P = 0.03); Loss of SUMOylation at K605 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K605 (Pr = 0.17 | P = 0.02), ELME000053|ELME000061|ELME000100|ELME000102|ELME000108|ELME000136|ELME000159|ELME000278|PS00004|PS00005,-
MYO7A_HUMAN,M622R,0.943,, ELME000012|ELME000062|ELME000102|ELME000108|ELME000125|ELME000331|ELME000336,-
MYO7A_HUMAN,A627S,0.274,-,-,-
MYO7A_HUMAN,E680Q,0.648,Loss of Allosteric site at R675 (Pr = 0.28 | P = 7.8e-03); Altered DNA binding (Pr = 0.21 | P = 0.02); Altered Disordered interface (Pr = 0.16 | P = 0.05), ELME000062|ELME000064|PS00006,-
MYO7A_HUMAN,G699N,0.261,-,-,-
MYO7A_HUMAN,R707H,0.201,-,-,-
MYO7A_HUMAN,M708I,0.234,-,-,-
MYO7A_HUMAN,M708L,0.445,-,-,-
MYO7A_HUMAN,T715A,0.268,-,-,-
MYO7A_HUMAN,D746N,0.529,Altered Disordered interface (Pr = 0.16 | P = 0.05); Altered DNA binding (Pr = 0.15 | P = 0.05), ELME000052|ELME000134|ELME000146|ELME000149|ELME000173|PS00005,-
MYO7A_HUMAN,V754I,0.184,-,-,-
MYO7A_HUMAN,N763H,0.311,-,-,-
MYO7A_HUMAN,N782S,0.219,-,-,-
MYO7A_HUMAN,N782Y,0.516,Altered DNA binding (Pr = 0.32 | P = 1.5e-03); Altered Disordered interface (Pr = 0.25 | P = 0.02); Altered Metal binding (Pr = 0.04 | P = 0.05), ELME000080|ELME000134|ELME000182,-
MYO7A_HUMAN,M790V,0.469,-,-,-
MYO7A_HUMAN,L792V,0.136,-,-,-
MYO7A_HUMAN,G793C,0.922,Altered Disordered interface (Pr = 0.29 | P = 0.01); Altered DNA binding (Pr = 0.26 | P = 6.7e-03), ELME000137,-
MYO7A_HUMAN,H801Q,0.221,-,-,-
MYO7A_HUMAN,R802Q,0.723,Altered Disordered interface (Pr = 0.45 | P = 4.4e-03); Altered DNA binding (Pr = 0.25 | P = 9.6e-03); Altered Coiled coil (Pr = 0.16 | P = 0.02), ELME000336,-
MYO7A_HUMAN,S803G,0.387,-,-,-
MYO7A_HUMAN,Q808E,0.149,-,-,-
MYO7A_HUMAN,Q808L,0.176,-,-,-
MYO7A_HUMAN,A813P,0.512,Altered Disordered interface (Pr = 0.45 | P = 4.6e-03); Altered Coiled coil (Pr = 0.14 | P = 0.03), ELME000012|ELME000233,-
MYO7A_HUMAN,F820L,0.364,-,-,-
MYO7A_HUMAN,L841F,0.275,-,-,-
MYO7A_HUMAN,W865R,0.038,-,-,-
MYO7A_HUMAN,E878Q,0.265,-,-,-
MYO7A_HUMAN,K887R,0.169,-,-,-
MYO7A_HUMAN,E910A,0.458,-,-,-
MYO7A_HUMAN,K914R,0.128,-,-,-
MYO7A_HUMAN,A919S,0.088,-,-,-
MYO7A_HUMAN,R921K,0.145,-,-,-
MYO7A_HUMAN,H934Q,0.077,-,-,-
MYO7A_HUMAN,T952I,0.208,-,-,-
MYO7A_HUMAN,S953P,0.396,-,-,-
MYO7A_HUMAN,R972H,0.083,-,-,-
MYO7A_HUMAN,L982V,0.055,-,-,-
MYO7A_HUMAN,T1018N,0.166,-,-,-
MYO7A_HUMAN,Y1028F,0.094,-,-,-
MYO7A_HUMAN,D1030E,0.133,-,-,-
MYO7A_HUMAN,K1056R,0.213,-,-,-
MYO7A_HUMAN,D1063N,0.347,-,-,-
MYO7A_HUMAN,K1080R,0.304,-,-,-
MYO7A_HUMAN,A1096T,0.071,-,-,-
MYO7A_HUMAN,P1099T,0.158,-,-,-
MYO7A_HUMAN,S1105T,0.087,-,-,-
MYO7A_HUMAN,E1124G,0.655,Altered Disordered interface (Pr = 0.35 | P = 5.5e-03); Loss of Helix (Pr = 0.28 | P = 0.02); Gain of Acetylation at K1128 (Pr = 0.24 | P = 0.01), ELME000052|ELME000053|ELME000063,-
MYO7A_HUMAN,V1137M,0.208,-,-,-
MYO7A_HUMAN,A1166G,0.376,-,-,-
MYO7A_HUMAN,I1171V,0.413,-,-,-
MYO7A_HUMAN,V1195M,0.221,-,-,-
MYO7A_HUMAN,Y1211F,0.369,-,-,-
MYO7A_HUMAN,E1248H,0.855,, ELME000064|PS00006,-
MYO7A_HUMAN,R1296H,0.476,-,-,-
MYO7A_HUMAN,S1356N,0.080,-,-,-
MYO7A_HUMAN,I1405V,0.104,-,-,-
MYO7A_HUMAN,N1411S,0.138,-,-,-
MYO7A_HUMAN,Y1477F,0.155,-,-,-
MYO7A_HUMAN,S1483H,0.471,-,-,-
MYO7A_HUMAN,N1487S,0.272,-,-,-
MYO7A_HUMAN,V1498I,0.537,Altered Transmembrane protein (Pr = 0.17 | P = 9.8e-03); Gain of N-linked glycosylation at N1494 (Pr = 0.03 | P = 0.03), ELME000070|ELME000080,-
MYO7A_HUMAN,M1517T,0.420,-,-,-
MYO7A_HUMAN,V1519M,0.561,Altered Stability (Pr = 0.13 | P = 0.03); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000064|ELME000239|ELME000336,-
MYO7A_HUMAN,C1533A,0.704,, ELME000007|ELME000053,-
MYO7A_HUMAN,D1535E,0.488,-,-,-
MYO7A_HUMAN,D1535G,0.628,, ELME000007|ELME000085|ELME000336|PS00008,-
MYO7A_HUMAN,P1541C,0.257,-,-,-
MYO7A_HUMAN,P1541T,0.218,-,-,-
MYO7A_HUMAN,T1549S,0.128,-,-,-
MYO7A_HUMAN,A1551P,0.482,-,-,-
MYO7A_HUMAN,P1556S,0.418,-,-,-
MYO7A_HUMAN,C1560S,0.249,-,-,-
MYO7A_HUMAN,A1563T,0.087,-,-,-
MYO7A_HUMAN,A1563V,0.090,-,-,-
MYO7A_HUMAN,T1565L,0.087,-,-,-
MYO7A_HUMAN,T1566A,0.102,-,-,-
MYO7A_HUMAN,T1566M,0.085,-,-,-
MYO7A_HUMAN,T1574A,0.578,Altered Transmembrane protein (Pr = 0.21 | P = 3.6e-03); Altered Stability (Pr = 0.19 | P = 0.01), PS00005,-
MYO7A_HUMAN,S1585T,0.299,-,-,-
MYO7A_HUMAN,K1603R,0.251,-,-,-
MYO7A_HUMAN,I1634V,0.100,-,-,-
MYO7A_HUMAN,H1637R,0.374,-,-,-
MYO7A_HUMAN,Q1642H,0.252,-,-,-
MYO7A_HUMAN,V1684I,0.133,-,-,-
MYO7A_HUMAN,V1694M,0.150,-,-,-
MYO7A_HUMAN,L1697F,0.173,-,-,-
MYO7A_HUMAN,R1701Q,0.118,-,-,-
MYO7A_HUMAN,A1709T,0.066,-,-,-
MYO7A_HUMAN,F1722V,0.771,Gain of Phosphorylation at Y1721 (Pr = 0.29 | P = 0.02); Loss of Sulfation at Y1721 (Pr = 0.05 | P = 9.2e-03), ELME000081|ELME000083|ELME000120|ELME000155|ELME000182,-
MYO7A_HUMAN,S1731A,0.410,-,-,-
MYO7A_HUMAN,R1732G,0.765,Altered Disordered interface (Pr = 0.52 | P = 2.1e-03); Loss of Helix (Pr = 0.28 | P = 0.03), ELME000085|PS00008,-
MYO7A_HUMAN,V1733A,0.331,-,-,-
MYO7A_HUMAN,M1734G,0.702,Altered Disordered interface (Pr = 0.30 | P = 0.01); Gain of Intrinsic disorder (Pr = 0.30 | P = 0.05); Loss of Helix (Pr = 0.28 | P = 0.03); Altered Stability (Pr = 0.17 | P = 0.02), PS00008,-
MYO7A_HUMAN,S1736R,0.267,-,-,-
MYO7A_HUMAN,K1737E,0.496,-,-,-
MYO7A_HUMAN,D1742A,0.578,Altered Disordered interface (Pr = 0.43 | P = 2.6e-03); Loss of Proteolytic cleavage at W1745 (Pr = 0.12 | P = 0.04), None,-
